Peter Greenleaf - 27 Feb 2026 Form 4 Insider Report for Aurinia Pharmaceuticals Inc. (AUPH)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: AUPH
Reported as of: 27 Feb 2026
Net transaction value: -$1,433,647
SEC form: 4
Accepted by SEC: 03 Mar 2026, 16:13:51 UTC
Prior SEC filing: 23 Feb 2026
Next SEC filing: 06 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Peter S. Greenleaf

Filing notes and source

Key filing fact

Peter Greenleaf filed Form 4 for Aurinia Pharmaceuticals Inc. (AUPH) on 03 Mar 2026.

Key facts

This page summarizes Peter Greenleaf's Form 4 filing for Aurinia Pharmaceuticals Inc. (AUPH).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Mar 2026, 16:13.

Change

Previous filing in this sequence was filed on 23 Feb 2026.
Current net transaction value: -$1,433,647.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001363683 Primary reporting owner

Greenleaf Peter

Relationship: Chief Executive Officer, Director
Address: #140, 14315-118 AVENUE, EDMONTON, ALBERTA, CANADA
Signature: /s/ Peter S. Greenleaf
Signature date: 03 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AUPH transaction

Common Stock

Award

Transaction value: $0
Shares: +196,403
Change %: +11%
Price: $0.000000
Shares after: 1,941,269
Date: 27 Feb 2026
Ownership: Direct
Footnotes: F1

AUPH transaction

Common Stock

Tax liability

Transaction value: $1,433,647
Shares: -100,890
Change %: -5.2%
Price: $14.21
Shares after: 1,840,379
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AUPH transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +328,424
Change %
Price: $0.000000
Shares after: 328,424
Date: 27 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 328,424
Exercise price: $13.97
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each performance right represents a contingent right to receive one common share of the Issuer. The performance rights vest in four tranches upon the Issuer's common shares achieving four progressively higher target prices, with respective one year retention periods per tranche achievement.

Footnote F2

Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

Footnote F3

One-third of the shares subject to the option vests twelve months from the grant date, and the remainder vests in twenty-four equal monthly installments thereafter.